Carolyn F. Deacon
Associate Professor
- Published
Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Deacon, Carolyn F., Ahrén, B. & Holst, Jens Juul, 2004, In: Expert Opinion on Investigational Drugs. 13, 9, p. 1091-102 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Deacon, Carolyn F., Carr, R. D. & Holst, Jens Juul, 2008, In: Frontiers in Bioscience. 13, p. 1780-94 14 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Differential regional metabolism of glucagon in anesthetized pigs.
Deacon, Carolyn F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M. & Holst, Jens Juul, 2003, In: American Journal of Physiology: Endocrinology and Metabolism. 285, 3, p. E552-60Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon, Carolyn F., 2007, In: Diabetes, Obesity and Metabolism. 9 Suppl 1, p. 23-31 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials
Deacon, Carolyn F., Feb 2018, In: Diabetes, Obesity and Metabolism. 20, p. 34-46 13 p.Research output: Contribution to journal › Review › Research › peer-review
- Published
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
Deacon, Carolyn F., Feb 2018, In: Peptides. 100, p. 150-157 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Advances in Therapy. 26, 5, p. 488-99 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
Deacon, Carolyn F., Plamboeck, A., Møller, Søren & Holst, Jens Juul, 2002, In: American Journal of Physiology: Endocrinology and Metabolism. 282, 4, p. E873-9Research output: Contribution to journal › Journal article › Research › peer-review
- Published
GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.
Deacon, Carolyn F., Plamboeck, A., Rosenkilde, Mette, de Heer, J. & Holst, Jens Juul, 2006, In: American Journal of Physiology: Endocrinology and Metabolism. 291, 3, p. E468-75Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon, Carolyn F., 2008, In: Current Opinion in Investigational Drugs. 9, 4, p. 402-13 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Therapeutic strategies based on glucagon-like peptide 1.
Deacon, Carolyn F., 2004, In: Diabetes. 53, 9, p. 2181-9 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.
Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Potential of liraglutide in the treatment of patients with type 2 diabetes
Deacon, Carolyn F., 2009, In: Vascular Health and Risk Management (Online). 5, 1, p. 199-211 12 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
MK-431 (Merck).
Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Immunoassays for the incretin hormones GIP and GLP-1
Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
Deacon, Carolyn F., Nauck, M. A., Meier, J., Hücking, K. & Holst, Jens Juul, 2000, In: Journal of Clinical Endocrinology and Metabolism. 85, p. 3575-3581Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo.
Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: Journal of Clinical Endocrinology and Metabolism. 80, p. 952-957Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
Deacon, Carolyn F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. & Holst, Jens Juul, 1998, In: Diabetologia. 41, p. 271-278Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects.
Deacon, Carolyn F., Nauck, M. A., Nielsen, M. T., Pridal, L. & Holst, Jens Juul, 1995, In: Diabetes. 44, p. 1126-1131Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.
Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes
Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170Research output: Contribution to journal › Journal article › Research › peer-review
ID: 9220
Most downloads
-
390
downloads
Glucagon-like peptide-1 receptor signaling in acinar cells causes growth dependent release of pancreatic enzymes
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
308
downloads
Acute effects of dietary carbohydrate restriction on glycemia, lipemia and appetite regulating hormones in normal-weight to obese subjects
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
303
downloads
Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
Research output: Contribution to journal › Journal article › Research › peer-review
Published